COURT-RULING ·Filed Sep 9, 2026

JNJ

JOHNSON & JOHNSON
NEUTRAL
Impact 1/10
Horizonmonths Processed21d 11h ago CourtView Ruling on CourtListener
Court ruling (district)
Actionable Insight • Neutral

This is a routine procedural ruling on a single case with no financial exposure stated. Monitor for any amended complaint filed by the September 30 deadline, but no trading action warranted.

DirectionNeutral
Confidencehigh
Horizonmonths
Latest settled — T+5d
JNJ ▲ +0.07% at T+5d
NEUTRAL call ✓ call won +0.07% · α vs SPY +0.73% · entry $267.08 → $267.28
Next anchor: T+20d in 4d
Latest observation: T+13 +0.43% FF3 residual α
Entry anchored
Sep 8, 07:50 PM ET
via 1-min bar
T+1d
-0.27%
call -0.27% · α +0.33%
$266.35
settled 23d ago
T+5d
+0.07%
call +0.07% · α +0.73%
$267.28
settled 17d ago
T+20d
—
call — · α —
—
in 4d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

A district court dismissed a product liability complaint against Johnson & Johnson without prejudice, granting leave to amend. The dismissal removes immediate litigation risk, but plaintiffs have until September 30, 2026 to file an amended complaint, keeping the case alive. For a $643.6B company, this single case is immaterial and does not move the stock.

Court Ruling Details

Ruling Date
Sep 9, 2026
Court
District Court of the Virgin Islands Division of St. Croix
Court Level
District
Judge
Robert A. Molloy
Case Type
product liability
Ruling Type
motion to dismiss
Outcome
WIN — ruling favors this company
Will It Be Appealed?
Unlikely
Precedent Risk
LOW

Key Facts

  • Court dismissed plaintiffs' amended complaint without prejudice
  • Plaintiffs have until September 30, 2026 to file an amended complaint
  • Case is a single product liability matter against Johnson & Johnson
  • No damages awarded, no injunction issued, no precedent risk

Financial Impact

No damages awarded or pleaded amount stated in the opinion; exposure is immaterial for a $643.6B company

Risk Factors

  • Plaintiffs may file an amended complaint by September 30, 2026, reviving the case
  • No material risk to Johnson & Johnson given the company's size and the isolated nature of this claim

Market Snapshot

Price
$266.29
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (31 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-50935ad91d-JNJ
16 reports for JNJ
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+60▲ +13.24%May 13, 2026
Filters
Rows
Reports for JNJ — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
Court Ruling
NEUTRAL ★ 1/10
$267.08 $267.28▲ +0.07%▲ +0.73%$258.14 (−3.35%)
Aug 18, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$273.41 $270.00▼ −1.25%▼ −0.86%$258.14 (−5.58%)
Aug 14, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$260.35 $270.24▲ +3.80%▲ +5.17%$258.14 (−0.85%)
Aug 7, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$261.81 $262.37▲ +0.21%▲ +0.26%$258.14 (−1.40%)
Aug 7, 2026
8w ago
Court Ruling
BEARISH ★ 4/10
$259.24 $260.35▼ −0.43%▼ −0.03%$258.14 (+0.42%)
Aug 4, 2026
8w ago
8-K
NEUTRAL ★ 2/10
$254.93 $259.80▲ +1.91%▲ +2.01%$258.14 (+1.26%)
Jul 22, 2026
10w ago
Court Ruling
BEARISH ★ 7/10
$255.63 $265.53▼ −3.87%▼ −6.27%$258.14 (−0.98%)
Jul 15, 2026
11w ago
8-K
BULLISH ★ 6/10
$247.02 $255.63▲ +3.49%▲ +4.47%$258.14 (+4.50%)
May 20, 2026
19w ago
Court Ruling
NEUTRAL ★ 1/10
$229.12 $231.29▲ +0.95%▼ −0.29%$258.14 (+12.67%)
May 13, 2026
20w ago
ANALYST-UPGRADE
BULLISH ★ 3/10
$230.79 $231.58▲ +0.34%▲ +1.06%$258.14 (+11.85%)
Showing 10 of 16

US Market Status

Market Open — Closes in 6h 28m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access